Exelixis Inc APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Exelixis Inc (EXEL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $32.70 million for the 3-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-07-03 was $32.70M, a 10.20% decline year-over-year.
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-04-03 was $29.20M, a 11.82% increase year-over-year.
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-01-02 was $20.19M, a 23.97% decline year-over-year.
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-10-03 was $31.12M, a 34.05% increase year-over-year.
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $113.85M, a 20.21% increase from fiscal 2025.
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $94.70M, a 11.83% decline from fiscal 2023.
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $107.41M, a 1.15% decline from fiscal 2022.
- Exelixis Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $108.66M, a 9.79% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-07-03 | $32.70M 10-Q · filed 2026-08-05 | $61.90M 10-Q · filed 2026-08-05 | $82.10M derived: sum of 3 quarters · filed 2026-08-05 | $113.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $29.20M 10-Q · filed 2026-05-05 | $49.40M derived: sum of 2 quarters · filed 2026-05-05 | $80.52M derived: sum of 3 quarters · filed 2026-05-05 | $116.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $20.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $51.32M derived: sum of 2 quarters · filed 2026-02-10 | $87.73M derived: sum of 3 quarters · filed 2026-08-05 | $113.85M 10-K · filed 2026-02-10 |
| 2025-10-03 | $31.12M 10-Q · filed 2025-11-04 | $67.54M derived: sum of 2 quarters · filed 2026-08-05 | $93.65M 10-Q · filed 2025-11-04 | $120.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $36.41M 10-Q · filed 2026-08-05 | $62.53M 10-Q · filed 2026-08-05 | $89.09M derived: sum of 3 quarters · filed 2026-08-05 | $112.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $26.12M 10-Q · filed 2026-05-05 | $52.68M derived: sum of 2 quarters · filed 2026-05-05 | $75.89M derived: sum of 3 quarters · filed 2026-05-05 | $101.49M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $26.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $49.78M derived: sum of 2 quarters · filed 2026-02-10 | $75.37M derived: sum of 3 quarters · filed 2026-02-10 | $94.70M 10-K · filed 2026-02-10 |
| 2024-09-27 | $23.22M 10-Q · filed 2025-11-04 | $48.81M derived: sum of 2 quarters · filed 2025-11-04 | $68.14M 10-Q · filed 2025-11-04 | $92.67M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $25.59M 10-Q · filed 2025-07-28 | $44.92M 10-Q · filed 2025-07-28 | $69.45M derived: sum of 3 quarters · filed 2026-02-10 | $110.28M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $19.33M 10-Q · filed 2025-05-13 | $43.86M derived: sum of 2 quarters · filed 2026-02-10 | $84.69M derived: sum of 3 quarters · filed 2026-02-10 | $109.85M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $24.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $65.36M derived: sum of 2 quarters · filed 2026-02-10 | $90.52M derived: sum of 3 quarters · filed 2026-02-10 | $107.41M 10-K · filed 2026-02-10 |
| 2023-09-29 | $40.83M 10-Q · filed 2024-10-29 | $65.99M derived: sum of 2 quarters · filed 2024-10-29 | $82.88M 10-Q · filed 2024-10-29 | $109.02M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $25.16M 10-Q · filed 2024-08-06 | $42.05M 10-Q · filed 2024-08-06 | $68.19M derived: sum of 3 quarters · filed 2025-02-11 | $105.80M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $16.89M 10-Q · filed 2024-04-30 | $43.02M derived: sum of 2 quarters · filed 2025-02-11 | $80.64M derived: sum of 3 quarters · filed 2025-02-11 | $105.53M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | $26.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $63.74M derived: sum of 2 quarters · filed 2025-02-11 | $88.64M derived: sum of 3 quarters · filed 2025-02-11 | $108.66M 10-K · filed 2025-02-11 |
| 2022-09-30 | $37.61M 10-Q · filed 2023-11-01 | $62.51M derived: sum of 2 quarters · filed 2023-11-01 | $82.52M 10-Q · filed 2023-11-01 | $105.96M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $24.89M 10-Q · filed 2023-08-01 | $44.91M 10-Q · filed 2023-08-01 | $68.35M derived: sum of 3 quarters · filed 2024-02-06 | $102.67M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | $20.02M 10-Q · filed 2023-05-09 | $43.45M derived: sum of 2 quarters · filed 2024-02-06 | $77.78M derived: sum of 3 quarters · filed 2024-02-06 | $105.81M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $23.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $57.76M derived: sum of 2 quarters · filed 2024-02-06 | $85.80M derived: sum of 3 quarters · filed 2024-02-06 | $120.45M 10-K · filed 2024-02-06 |
| 2021-10-01 | $34.32M 10-Q · filed 2022-11-01 | $62.36M derived: sum of 2 quarters · filed 2022-11-01 | $97.01M 10-Q · filed 2022-11-01 | $116.29M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $28.04M 10-Q · filed 2022-08-09 | $62.69M 10-Q · filed 2022-08-09 | $81.97M derived: sum of 3 quarters · filed 2023-02-07 | $137.62M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $34.65M 10-Q · filed 2022-05-10 | $53.93M derived: sum of 2 quarters · filed 2023-02-07 | $109.59M derived: sum of 3 quarters · filed 2023-02-07 | $125.74M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $19.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $74.93M derived: sum of 2 quarters · filed 2023-02-07 | $91.09M derived: sum of 3 quarters · filed 2023-02-07 | $105.07M 10-K · filed 2023-02-07 |
| 2020-10-02 | $55.66M 10-Q · filed 2021-11-02 | $71.81M derived: sum of 2 quarters · filed 2021-11-02 | $85.79M 10-Q · filed 2021-11-02 | $101.65M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $16.15M 10-Q · filed 2021-08-05 | $30.14M 10-Q · filed 2021-08-05 | $45.99M derived: sum of 3 quarters · filed 2022-02-18 | $59.13M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $13.98M 10-Q · filed 2021-05-06 | $29.84M derived: sum of 2 quarters · filed 2022-02-18 | $42.98M derived: sum of 3 quarters · filed 2022-02-18 | $58.05M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | $15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $28.99M derived: sum of 2 quarters · filed 2022-02-18 | $44.07M derived: sum of 3 quarters · filed 2022-02-18 | $56.60M 10-K · filed 2022-02-18 |
| 2019-09-27 | $13.14M 10-Q · filed 2020-11-05 | $28.22M derived: sum of 2 quarters · filed 2020-11-05 | $40.75M 10-Q · filed 2020-11-05 | $53.04M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-28 | $15.08M 10-Q · filed 2020-08-06 | $27.61M 10-Q · filed 2020-08-06 | $39.90M derived: sum of 3 quarters · filed 2020-08-06 | $49.65M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-29 | $12.53M 10-Q · filed 2020-05-05 | $24.82M derived: sum of 2 quarters · filed 2020-05-05 | $34.57M derived: sum of 3 quarters · filed 2020-05-05 | $43.85M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-28 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $22.04M derived: sum of 2 quarters · filed 2020-02-25 | $31.32M derived: sum of 3 quarters · filed 2020-02-25 | $40.63M 10-K · filed 2021-02-11 |
| 2018-09-28 | $9.74M 10-Q · filed 2019-10-30 | $19.02M derived: sum of 2 quarters · filed 2019-10-30 | $28.33M 10-Q · filed 2019-10-30 | |
| 2018-06-29 | $9.28M 10-Q · filed 2019-07-31 | $18.59M 10-Q · filed 2019-07-31 | ||
| 2018-03-30 | $9.30M 10-Q · filed 2019-05-01 | |||
| 2017-12-29 | $23.94M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $22.91M 10-K · filed 2017-02-27 | |||
| 2016-12-30 | $22.91M 10-K · filed 2019-02-22 | |||
| 2016-01-01 | $21.98M 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $21.98M 10-K · filed 2017-02-27 | |||
| 2014-12-31 | $10.01M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |